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Objectives: Lung cancer is one of the most common causes of cancer-related 
deaths world-wide. Afatinib is an irreversible ErbB family blocker showing superior 
efficacy in EGFRm+ NSCLC as 1st-line treatment compared to standard-of-care 
chemotherapy. To date, no head-to-head trial results exist to compare afatinib, gefi-
tinib or erlotinib. Previous NMAs have compared the three treatments on an ITT 
level, but not by mutation type. This analysis attempts to fill this gap. MethOds: 
Based on the EGFRm+ study network requested by NICE a Bayesian approach NMA 
was conducted to estimate relative treatment effects of afatinib versus erlotinib and 
gefitinib for progression free survival (PFS) and overall survival (OS) per mutation 
type (common mutations: Del19 and L858R). Results: 9 studies were included, 
8 reported PFS and 5 OS by mutation type, respectively. Results from fixed effects 
models are reported. Afatinib significantly improved PFS in common mutations 
versus gefitinib (HR 0.43: CrI 0.24; 0.75) and erlotinib (HR 0.60; CrI 0.39; 0.91). Results 
also favored afatinib for both EGFR mutation subgroups Del19 and L858R, but did 
not reach statistical significance. Afatinib showed a high probability (> 80%) of being 
the best treatment both for common mutations and per mutation type. For OS, a 
trend favoring afatinib was shown in particular for Del19. The probability of afatinib 
being best for Del19 was > 70%. For L858R no difference in OS was detected between 
the TKIs. cOnclusiOns: In line with findings from previous NMAs, this analysis 
by mutation type confirms both for PFS and OS a consistent trend towards supe-
riority of afatinib versus reversible TKIs. Afatinib appears to be the best treatment 
option for patients with common mutations, in particular Del19 mutations. A direct 
trial-based comparison of the efficacy of these agents is warranted to clarify their 
relative benefits.
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Objectives: This analysis described health care costs over time—excluding ipili-
mumab drug costs—stratified by survival duration and baseline ECOG status, in 
patients receiving ipilimumab for advanced melanoma in the US community set-
ting. MethOds: We analyzed data from a retrospective chart review of patients 
with unresectable stage III/IV melanoma treated with ipilimumab as first-line 
monotherapy between 04/2011 and 09/2012. Hospitalizations, emergency depart-
ment visits, subsequent chemotherapy, radiation, surgeries, nursing home, and 
hospice visits costs were estimated using published sources and tariffs. Total costs, 
excluding ipilimumab drug costs, were calculated for 3 periods: treatment regimen 
(between first and last ipilimumab doses); post-regimen; and pre-death (within 90 
days of death). Monthly costs were compared for the total population and stratified 
by baseline ECOG status (0 vs. ≥ 1, when available) and survival (< 1 year vs. ≥ 1 year) 
using Wilcoxon rank sum tests. Results: Data were abstracted from 273 patient 
charts at 34 sites. Excluding ipilimumab drug costs, total monthly costs during the 
treatment regimen, post-regimen, and pre-death periods were $690, $2151, and 
$5123, respectively. Total monthly costs across all study periods were higher for 
patients with ECOG ≥ 1 (n= 135) vs. ECOG= 0 (n= 104) (p= 0.0294), particularly in the 
pre-death period ($5987 vs. $3460, respectively; p= 0.0143). A similar pattern was 
observed for patients surviving < 1 year (n= 109) vs. ≥ 1 year (n= 122) (p< 0.0001), with 
a difference of $9524 vs. $2955 (p< 0.0001) during the pre-death period (42 patients 
still alive after < 1 year follow-up were excluded from this analysis). Key cost drivers 
were hospitalizations (32.4% of total costs), followed by non-ipilimumab chemother-
apy (23.1%), hospice care (19.1%), and nursing home stays (12.5%). cOnclusiOns: 
In this population, monthly costs were significantly lower during the treatment 
regimen period than in subsequent periods. Survival ≥ 1 year and baseline ECOG= 0 
were associated with significantly lower total monthly costs, particularly in the 
pre-death period.
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Objectives: No standard of care exists for patients with relapsed or refractory 
mantle cell lymphoma (MCL) and treatment options are limited. This study sought 
to synthesize the clinical evidence of current treatments for relapsed or refractory 
MCL, its limitations, and discuss the implications for decision making. MethOds: 
A systematic literature review was conducted in MEDLINE of phase II, III, or IV 
clinical trials published in English between January 1, 2001 and May 2, 2013. 
Supplemental searches included EHA, AACR, ASCO, and ASH 2011–2013 confer-
ence proceedings. Results: Results of the review indicate a paucity of evidence 
relevant for decision making. Of 808 records reviewed, 17 trials in the R/R MCL 
population were identified, only three of which were randomized controlled trials; 
all others were single-arm trials. For most treatments, only one trial was available. 
These factors made it infeasible to conduct a meta-analysis or indirect comparison. 
Furthermore, there was a large amount of heterogeneity in the patient popula-
tions, trial designs, and reported outcomes, making it difficult to compare outcomes 
across trials. Finally, of the 17 trials identified, five reported progression-free sur-
vival (PFS) Kaplan–Meier (K-M) graphs and only three reported overall survival (OS) 
of ibrutinib to available treatments for R/R MCL patients. MethOds: A systematic 
literature review was conducted to identify clinical trials containing treatments of 
R/R MCL. Matching adjusted indirect comparison (MAIC), described by Signorovitch 
et al 2012, was utilized to obtain indirect relative treatment effect for ibrutinib 
compared to other treatments. Using individual patient level data (IPD), baseline 
characteristics of the ibrutinib trial patients were matched with the patients in the 
published studies to obtain overall response (ORR) and complete response (CR) rates 
based on balanced population between the ibrutinib and published studies. Kaplan 
Meir curves for overall survival and PFS of comparators were plotted alongside those 
of the matched ibrutinib patients. Results: Nineteen studies evaluating various 
treatments were identified. Five trials evaluating bortezomib, BR (bendamustine, 
rituximab), FCM (fludarabine, cyclophosphamide, mitoxantrone), FCM-R (fludara-
bine, cyclophosphamide, mitoxantrone, rituximab), and rituximab-hyper-CVAD 
were considered for matching. Complete matching of the IPD was possible for the 
bortezomib, FCM and FCM-R studies. Ibrutinib showed statistically significant bet-
ter odds of achieving ORR compared to bortezomib (OR 3.62; 95% CI 1.18-11.14) and 
FCM (OR 3.22; 95% CI 1.01-10.26). cOnclusiOns: The indirect analysis suggests a 
potential for improved ORR compared to a few relevant treatments in patients with 
R/R MCL. Phase III comparative confirmatory data with ibrutinib are anticipated 
in late 2014.
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Objectives: The NSABP/NCCTG trial (Romond et al. NEJM 2005; 353: 1673-1684) 
established the efficacy of trastuzumab in the adjuvant treatment of HER2+ early 
stage breast cancer (HER2+BC). Yet, little is known about the patterns of use and 
outcomes of adjuvant trastuzumab in clinical practice. The study aimed to esti-
mate the overall survival (OS) and relapse-free survival (RFS) of HER2+BC patients 
treated with adjuvant trastuzumab in the US Department of Defense (DOD) prac-
tice setting. MethOds: Adult women initiating adjuvant trastuzumab within 1 
year of BC surgery were identified in the DOD health claims database (01/2003-
12/2012). An algorithm based on secondary neoplasm ICD9 codes and treatment 
gaps and initiations was used to identify relapses. OS and RFS unadjusted rates 
at 3 and 4 years after the initiation of the adjuvant trastuzumab treatment were 
estimated from Kaplan-Meier plots. Results: The study sample included 3,188 
women (median age 63 years), followed for a median of 3.3 years after the initia-
tion of trastuzumab and treated continuously with trastuzumab for a median of 
12 months. Of these 3,188 women, 13.8% received neo-adjuvant therapy prior to 
the surgery, 17.7% relapsed, and 7.9% died during the follow-up. The OS rates at 3 
and 4 years were 93.2% (95% CI 92.1%-94.2%) and 90.0% (88.6%-91.2%), respectively. 
The corresponding RFS rates were 78.8% (77.1%-80.3%) and 75.8% (74.0%-77.5%), 
respectively. cOnclusiOns: The findings suggest that most HER2+BC patients in 
the DOD practice setting received per-label trastuzumab treatment (for 52 weeks) 
and had OS rates that are similar to the OS rates that were previously observed 
in the NSABP/NCCTG clinical trial (90.0% vs. 93% at four years). The lower RFS 
rates observed in this study versus the NSABP/NCCTG trial (75.8% vs. 85.7% at 
4 years), may be partially explained by differences in the characteristics of the 
patients, including age.
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Objectives: To assess the relative efficacy of first-line treatments in chronic mye-
loid leukaemia (CML), an updated systematic literature review (SLR) and indirect 
comparison (IC) were conducted with follow-up period up to 48 months. MethOds: 
We updated a SLR initially conducted in 2011. Medical databases were interrogated 
systematically in January 2014 to identify trials comparing first-line treatments for 
CML. Using a fixed-effect Bayesian model implemented in WinBUGS, ICs were made 
to calculate relative efficacy (cumulative complete cytogenetic response (CCyR) and 
major molecular response (MMR)) for dasatinib, nilotinib and imatinib. Results: 
Nineteen randomised controlled trials (RCTs) were included in the SLR, 10 were 
eligible for inclusion in the IC. Compared with imatinib 400mg by 12 months, odds 
of cumulative CCyR were significantly greater for dasatinib 100mg [odds ratio (OR) 
2.25,95% credible interval (CrI) 1.55-3.15], nilotinib 600mg [OR 2.23 (95% CrI 1.50-
3.21)] and 800mg [OR 1.94 (95% CrI 1.31-2.78)]. By 24 months compared with imatinib 
400mg, the odds remained significantly higher with nilotinib 600mg [OR 2.03 (95% 
CrI 1.28-3.10)] and 800mg [OR 1.70 (95% CrI 1.08-2.55)] and higher, but not signifi-
cant with dasatinib 100mg [OR 1.41 (95% CrI 0.85-2.22)]. By 12,24,36 and 48 months 
respectively, compared with imatinib 400mg, the odds of a MMR were: dasatinib 
100mg [OR 2.22 (95% CrI 1.52-3.15) / 2.09 (1.45-2.93) / 1.76 (1.22-2.48) / 1.90 (1.27-2.74)] 
nilotinib 600mg [OR 2.86 (95% CrI 1.95-4.08) / 3.24 (2.26-4.54) / 2.45 (1.70-3.43) / 2.54 
(1.75-3.59)] and 800mg [OR 2.76 (95% CrI 1.88-3.94) / 2.60 (1.82-3.62) / 2.12 (1.48-2.95)/ 
2.18 (1.51-3.06)]. For both outcomes at all time points, there was no significant differ-
ence between dasatinib and nilotinib. cOnclusiOns: Analysis including all avail-
able RCTs suggests that second-generation tyrosine kinase inhibitors dasatinib and 
nilotinib are more efficacious than imatinib 400mg and should be treatments of 
choice in newly diagnosed CML.
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cal data for lung metastasis, primary and secondary liver cancer, locally advanced 
pancreatic cancer population treated with CyberKnife radiation. Searching using 
Medline, EMBASE, Cochrane Library took place in September 2013. Results: Only 
one relevant comparative clinical study (matched-pair analysis) met the inclusion 
criteria, assessing effectiveness and safety of stereotactic radiosurgery and radi-
ofrequency ablation for colorectal liver metastasis. For other neoplasms single-arm 
studies were found. Compared to RFA CyberKnife for liver metastasis was signifi-
cantly better in median local disease free survival, which was 34.4 months vs. 6.0 
months, (p< 0.001). 1 and 2-year local control rates also favored CK (85.0% vs. 65.0% 
and 80.0% vs. 61.0%, respectively) but the difference wasn’t significant. However, 
trend for better OS was found with RFA (34.4 vs. 52.3 months). For lung metastasis, 
treatment with CK resulted in 24.0-62.0% complete or partial response, 38.0-76.0% 
patients stabilized. In primary liver tumors OR (CR + PR) was observed in 63.0-86.0% 
patients, 0.0-29.0% stabilized, median PFS reached 10.0-15.8 months. Inconsistent 
results were seen in locally advanced pancreatic cancer population. In one study 
92.0% responded or stabilized but in other only 1 patient of 77 had PR. Median OS 
was 6.4-10.3 months. All studies reported mostly mild adverse events after CK. 
Serious AE were rare. cOnclusiOns: There is limited quality evidence on the 
effectiveness and safety of robotic image-guided stereotactic radiosurgery in 
patients with soft tissue neoplasms. Available studies are highly heterogenic in 
methods, patients characteristics and outcomes but suggest that CyberKnife may 
be beneficial in local tumor control. There is a need of well-designed comparative 
studies.
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Objectives: For patients with relapsed or refractory (R/R) chronic lymphocytic 
leukemia (CLL), treatment outcomes are poor and treatment options are limited. 
Ibrutinib is an oral, once-a-day, first-in-class covalent inhibitor of Bruton’s tyrosine 
kinase approved by the Food and Drug Administration (FDA) for R/R CLL. In a recent 
phase III trial (PCYC-1112), ibrutinib was associated with improved progression-free 
survival (PFS, hazard ratio [HR] = 0.215) and overall survival (OS, HR= 0.387) versus 
ofatumumab. The aim of this study is to provide a summary and analysis of results 
observed with current therapies in high-risk patients with R/R CLL. MethOds: 
A systematic literature review and targeted literature search of clinical trials and 
international treatment guidelines in PubMed/MEDLINE (January 1,2001–April 
28,2013) and ASCO/ASH/EHA conference proceedings (2011–2013) were conducted 
to identify and evaluate current treatment options for R/R CLL, including alem-
tuzumab, rituximab, bendamustine, chlorambucil, and ofatumumab. Results: 
Study results highlight poor outcomes with existing treatment options and 
continuously high unmet need in patients. Sixteen trials were identified; the 
majorities were single-arm with small sample sizes, making comparative effec-
tiveness difficult to establish. Time-to-treatment failure was 5.8 months with 
alemtuzumab, while median PFS was 5.5 months with rituximab, 5.5–5.7 months 
with ofatumumab, 8 months with chlorambucil-ritiximab, and 15.2 months in 
previously-treated patients and 6.8 months in previously-treated patients with 
del (17p) with bendamustine-rituximab. Ofatumumab has demonstrated activ-
ity in patients with difficult-to-treat, high-risk CLL and is the only recognized 
and approved treatment by health authorities globally in this treatment setting 
and recommended in treatment guidelines. cOnclusiOns: The lack of standard 
of care creates challenges for defining comparators in clinical trials and health 
technology assessments. In R/R CLL with high-risk features, ofatumumab is an 
appropriate comparator. Interim results from the phase III RESONATE trial showed 
that ibrutinib achieved significantly improved efficacy versus ofatumumab, even 
in high-risk disease patients.
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Objectives: MTC is a rare form of thyroid cancer with prevalence of less than 7 per 
100,000. A majority of MTC patients have RET mutations, and RET M918T mutations 
are associated with especially poor prognosis. In 2012, EMA approved the first tyros-
ine kinase inhibitor (TKI) CAPRELSA® (vandetanib, VDB) for the treatment of MTC. 
In March 2014, the EMA approved another TKI -COMETRIQ® (cabozantinib, CBZ) for 
the treatment of adult patients with progressive, unresectable locally advanced or 
metastatic MTC, with orphan drug status. The objective of this study was to assess the 
relative efficacy in PFS and OS of CBZ vs VDB. MethOds: Since there are no clinical 
trials directly comparing the two treatments, an adjusted indirect comparison (Bucher 
et al. method) was used. Evidence on PFS for the two treatments was collected from 
the pivotal clinical trials in MTC. The analysis considered all patients and a subgroup 
of RET M918T mutation positive (RET+) patients. Our analysis focused on PFS due 
to lack of evidence for the VDB OS in the RET M918T mutation subgroup. In the all 
patients analysis three different scenarios were explored: a logrank model to ensure 
comparability with the VDB data; a Cox model stratified on age at randomization and 
prior TKI status; and a Cox model without stratifications. Results: In the subgroup 
analysis (logrank model) PFS was estimated to increase by 65% with CBZ comparing 
to VDB (HR 0.35; 95% CI 0.14-0.87). In the all-patients analysis the estimates were less 
conclusive: logrank model (HR 0.72; 0.40-1.28), Cox model with stratifications (HR 0.61; 
0.35-1.04), Cox model without stratifications (HR 0.66; 0.39-1.13). cOnclusiOns: The 
results showed a positive trend in favour of CBZ in PFS. Given the limited evidence a 
direct head-to-head comparison is necessary to validate the study findings.
K-M graphs. cOnclusiOns: Due to very limited availability of trials with robust 
endpoints and long-term follow-up, alternative options for establishing compara-
tive efficacy must be used for decision making in relapsed or refractory MCL. These 
alternatives include implementing comparisons of single-arm trial data without 
adjustment (i.e., via naïve comparison) or methods such as match-adjusted indi-
rect comparison (MAIC) to derive comparative estimates. MAIC is a relatively novel 
method and may be difficult to implement given the heterogeneity in trial designs 
and patient-level characteristics in MCL trials. The scarcity of K-M data to inform 
PFS and OS of certain comparators further limits the comparisons that can be made 
through modeling.
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Objectives: The prognosis of patients with metastatic cervical cancer (CC) remains 
poor, and treatment options are limited, with no single agent or combination of 
agents recognised as standard of care; cisplatin/paclitaxel is the therapy most cited 
by guidelines. This study aimed to assess the efficacy of reported treatment options 
for patients with metastatic CC. MethOds: Searches of PubMed were conducted, 
with no date restrictions, to identify published randomised controlled Phase II/III 
clinical trials (RCTs) of chemotherapies recommended by treatment guidelines, 
and radiotherapy and/or surgery, that reported overall survival (OS) in patients with 
metastatic (systemic recurrent, persistent or de novo-metastatic) CC. Treatment 
guidelines and the Cochrane Library were also explored to identify additional cita-
tions. Results: Of 65 articles identified, 10 articles published between 1987 and 
2014 proceeded to data extraction. Evidence supporting the use of chemotherapy 
was limited to cisplatin-monotherapy or platinum-based combination therapy. 
Overall the OS benefit of these agents ranged from 0.9 to 2.9 months and 0.79 to 
1.32 for hazard ratio (HR). The latest innovation, bevacizumab plus chemotherapy, 
demonstrated the greatest significant gain in OS versus chemotherapy (OS gain 
3.7 months; HR 0.71; p= 0.004). The study did not identify any RCTs that supported 
the use of surgery and/or radiotherapy in this setting; the evidence was limited to 
seven retrospective hospital based studies. cOnclusiOns: This study highlighted 
an unmet need for additional treatment options for metastatic CC. Use of cispl-
atin-monotherapy or platinum-based combination therapy has provided limited 
survival benefits for many decades. The novel combination of bevacizumab plus 
chemotherapy has demonstrated an increase in survival in these patients. However, 
since there is no RCT evidence supporting the use of surgery and/or radiotherapy, 
a health technology appraisal of these alternative interventions is not currently 
feasible. Additional clinical research is urgently needed to assess the comparative 
clinical value of these therapies.
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Objectives: Abiraterone acetate plus predniso(lo)ne (AA) and enzalutamide (E) 
are novel therapies for the treatment of metastatic castration-resistant prostate 
cancer in chemotherapy naïve patients. Pivotal trials have been conducted evalu-
ating the efficacy of the drugs using different comparators. In the COU-AA-302 
trial, patients were randomised between AA and active comparator predniso(lo)
ne whereas in the PREVAIL trial, E was compared against placebo. For health 
economic purposes, the mean overall survival (OS) and radiographic progression-
free survival (rPFS) of both novel agents need to be compared in the absence 
of head-to-head trial data. MethOds: Due to the difference in the comparator 
arms, only survival data from AA and E were used for the comparison. Observed 
individual level survival data with baseline patient characteristics were available 
for AA. Individual survival data were simulated for E to replicate the rPFS and OS 
curves published for the pivotal trial. rPFS and OS were modeled and extrapolated 
by fitting parametric survival functions. The Weibull, exponential, and lognor-
mal models were evaluated based on statistical and clinical considerations, i.e. 
assessing the model fit and the implied hazard profiles, respectively. To control 
for differences in baseline patient characteristics (PSA, ECOG, Gleason score, BPI, 
LDH, metastasis, age, race) rPFS and OS estimates for AA were adjusted using a 
matching algorithm. Results: The Weibull models were selected for extrapo-
lation of both OS and rPFS. The mean rPFS was estimated to be 23.9 (95% CI: 
21.5-26.3) and 19.5 (95% CI: 16.0-23.9) months for AA and E respectively. Mean OS 
was estimated to be 38.7 (95% CI: 36.4-40.7) and 34.6 (95% CI: 31.8-37.8) months 
respectively. cOnclusiOns: Based on currently available data and the presented 
modeling approach, these findings suggest that AA is associated with longer mean 
rPFS and OS than E.
PCN13
CLiNiCaL effeCTiveNess of roboTiC imaGe-Guided sTereoTaCTiC 
radiosurGery (CyberkNife) iN seLeCTed Primary aNd seCoNdary sofT 
Tissue NeoPLasms: a sysTemaTiC review
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Objectives: Effectiveness of radiosurgery for head and spinal neoplasms is 
established. The aim of this study was to systematically review the clinical lit-
erature of CyberKnife for people with selected primary and secondary soft tissue 
lesions. MethOds: A systematic search was conducted for best available clini-
